The in vivo mechanisms underlying dominant syndromes caused by mutations in SRY-Box Transcription Factor 9 ( SOX9 ) and SOX10 ( SOXE ) transcription factors, when they either are expressed alone or are coexpressed, are ill-defined. We created a mouse model for the campomelic dysplasia
SOX9
Y440X mutation, which truncates the transactivation domain but leaves DNA binding and dimerization intact. Here, we find that
SOX9
Y440X causes deafness via distinct mechanisms in the endolymphatic sac (ES)/duct and cochlea. By contrast, conditional heterozygous Sox9 -null mice are normal. During the ES development of
Sox9
Y440X/+ heterozygotes, Sox10 and genes important for ionic homeostasis are down-regulated, and there is developmental persistence of progenitors, resulting in fewer mature cells. Sox10 heterozygous null mutants also display persistence of ES/duct progenitors. By contrast, SOX10 retains its expression in the early
Sox9
Y440X/+ mutant cochlea. Later, in the postnatal stria vascularis, dominant interference by SOX9 Y440X is implicated in impairing the normal cooperation of SOX9 and SOX10 in repressing the expression of the water channel Aquaporin 3, thereby contributing to endolymphatic hydrops. Our study shows that for a functioning endolymphatic system in the inner ear, SOX9 regulates Sox10 , and depending on the cell type and target gene, it works either independently of or cooperatively with SOX10. SOX9 Y440X can interfere with the activity of both SOXE factors, exerting effects that can be classified as haploinsufficient/hypomorphic or dominant negative depending on the cell/gene context. This model of disruption of transcription factor partnerships may be applicable to congenital deafness, which affects ∼0.3% of newborns, and other syndromic disorders.
30 December 2022 in Proceedings of the National Academy of Sciences
Haploinsufficiency for SOX9, the master chondrogenesis transcription factor, can underlie campomelic dysplasia (CD), an autosomal dominant skeletal malformation syndrome, because heterozygousSox9null mice recapitulate the bent limb (campomelia) and some other phenotypes associated with CD. However, in vitro cell assays suggest haploinsufficiency may not apply for certain mutations, notably those that truncate the protein, but in these cases in vivo evidence is lacking and underlying mechanisms are unknown. Here, using conditional mouse mutants, we compared the impact of a heterozygousSox9null mutation (Sox9+/−) with theSox9+/Y440XCD mutation that truncates the C-terminal transactivation domain but spares the DNA-binding domain. While someSox9+/Y440Xmice survived, allSox9+/−mice died perinatally. However, the skeletal defects were more severe and IHH signaling in developing limb cartilage was significantly enhanced inSox9+/Y440Xcompared withSox9+/−. ActivatingSox9Y440Xspecifically in the chondrocyte–osteoblast lineage caused milder campomelia, and revealed cell- and noncell autonomous mechanisms acting on chondrocyte differentiation and osteogenesis in the perichondrium. Transcriptome analyses of developingSox9+/Y440Xlimbs revealed dysregulated expression of genes for the extracellular matrix, as well as changes consistent with aberrant WNT and HH signaling. SOX9Y440Xfailed to interact with β-catenin and was unable to suppress transactivation ofIhhin cell-based assays.We propose enhanced HH signaling in the adjacent perichondrium induces asymmetrically localized excessive perichondrial osteogenesis resulting in campomelia. Our study implicates combined haploinsufficiency/hypomorphic and dominant-negative actions of SOX9Y440X, cell-autonomous and noncell autonomous mechanisms, and dysregulated WNT and HH signaling, as the cause of human campomelia.
3 October 2024 in European Journal of Human Genetics
Prenatal sequencing tests are being introduced into clinical practice in many developed countries. In part due to its greater ability to detect genetic variation, offering prenatal sequencing can present ethical challenges. Here we review ethical issues arising following the implementation of prenatal sequencing in the English National Health Service (NHS). We analysed semi structured interviews conducted with 48 parents offered prenatal sequencing and 63 health professionals involved in delivering the service to identify the ethical issues raised. Two main themes were identified: (1) Equity of access (including issues around eligibility criteria, laboratory analytical processes, awareness and education of clinicians, fear of litigation, geography, parental travel costs, and access to private healthcare), and (2) Timeliness and its impact on parental decision-making in pregnancy (in the context of the law around termination of pregnancy, decision-making in the absence of prenatal sequencing results, and the “importance” of prenatal sequencing results). Recognising both the practical and systemic ethical issues that arise out of delivering a national prenatal sequencing service is crucial. Although specific to the English context, many of the issues we identified are applicable to prenatal sequencing services more broadly. Education of health professionals and parents will help to mitigate some of these ethical issues.
Background: Social media groups (SMGs) enable individuals with rare diseases to connect with one another and access instant support and advice. Accelerated diagnoses of genetic neurodevelopmental disorders (NDDs) over the last decade have driven rapid expansion of gene-specific SMG membership. Limited literature regarding parental use of SMGs in the context of managing their child’s NDD exists. Objective: The objective of our study was to determine and describe how parents use social media and the internet in the context of their child’s NDD. Methods: We undertook a mixed methods study of 477 parents within a cohort of children with NDDs (Genetic Rare Disease: Observational Cohort Study; GenROC). A total of 359 parents provided quantifiable survey responses regarding their use of social media. We also interviewed 17 parents to understand how they use SMGs and their views on the data held within these groups. Results: Our survey found 359/475 (75.7%) of parents use SMGs related to their child’s genetic disorder, and of these, 98.5% (354/359) are on Facebook. Most SMGs are closed, international, have more than 200 members, are specific to the NDD, and are associated with a corresponding charity or foundation. In total, 191/312 (61.2%) parents could not recall what they had consented to when joining the group with respect to the use of their posted data. Most parents trust the data (Likert scale 1‐10; mean 7.03, SD 1.98) that are shared but acknowledged the anecdotal nature of them. Parents found the most valuable element of the SMG to be shared lived experience with other families. Interview data from 17 parents were coded and analyzed thematically. A total of 4 main themes were identified: (1) SMGs for support and shared lived experience; (2) possible harms from participation in SMGs; (3) SMG composition, demographics, and dynamics; and (4) usefulness and use of data shared within the groups. Conclusions: This mixed methods study shows the evolving landscape of SMG use in neurodevelopmental disorders, highlights its benefits and downsides, and is widely applicable to all parent SMGs for specific niche medical conditions. Using the strength of these groups in a more collaborative approach in the future could prove useful to clinicians, families, and researchers alike.